116 related articles for article (PubMed ID: 3047614)
1. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses.
Finkler NJ; Benacerraf B; Lavin PT; Wojciechowski C; Knapp RC
Obstet Gynecol; 1988 Oct; 72(4):659-64. PubMed ID: 3047614
[TBL] [Abstract][Full Text] [Related]
2. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
[TBL] [Abstract][Full Text] [Related]
3. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer.
Zurawski VR; Broderick SF; Pickens P; Knapp RC; Bast RC
Obstet Gynecol; 1987 Apr; 69(4):606-11. PubMed ID: 2434895
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses.
O'Connell GJ; Ryan E; Murphy KJ; Prefontaine M
Obstet Gynecol; 1987 Dec; 70(6):930-2. PubMed ID: 3479735
[TBL] [Abstract][Full Text] [Related]
5. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses.
Chen DX; Schwartz PE; Li XG; Yang Z
Obstet Gynecol; 1988 Jul; 72(1):23-7. PubMed ID: 3164105
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum tumor-associated antigen levels in women with pelvic masses.
Soper JT; Hunter VJ; Daly L; Tanner M; Creasman WT; Bast RC
Obstet Gynecol; 1990 Feb; 75(2):249-54. PubMed ID: 2300353
[TBL] [Abstract][Full Text] [Related]
8. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease.
Malkasian GD; Knapp RC; Lavin PT; Zurawski VR; Podratz KC; Stanhope CR; Mortel R; Berek JS; Bast RC; Ritts RE
Am J Obstet Gynecol; 1988 Aug; 159(2):341-6. PubMed ID: 2457318
[TBL] [Abstract][Full Text] [Related]
9. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index.
Enakpene CA; Omigbodun AO; Goecke TW; Odukogbe AT; Beckmann MW
J Obstet Gynaecol Res; 2009 Feb; 35(1):131-8. PubMed ID: 19215560
[TBL] [Abstract][Full Text] [Related]
10. Serum CA 125 levels in preoperative evaluation of pelvic masses.
Vasilev SA; Schlaerth JB; Campeau J; Morrow CP
Obstet Gynecol; 1988 May; 71(5):751-6. PubMed ID: 3162763
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
García Enguídanos A; Crespo Azanza E; Díaz Recaséns J; Lobo Samper F; Jorge Herrero JA; Sáinz de la Cuesta Abbad R
Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of a cancer antigen, CA 125, associated with ovarian cancer. I. Technical investigation and the reference value].
Sakurabayashi I; Kawai T; Suzuki M; Tamada T; Sato K; Yonezawa M
Rinsho Byori; 1984 Dec; 32(12):1345-9. PubMed ID: 6597875
[No Abstract] [Full Text] [Related]
14. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
15. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.
Koebl H; Tatra G; Bieglmayer C
Neoplasma; 1988; 35(2):215-20. PubMed ID: 3259680
[TBL] [Abstract][Full Text] [Related]
18. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic significance of preoperative determination of CA-125 serum levels in the differentiation of malignant and benign pelvic masses].
Durdević S; Segedi D; Vejnović T; Radeka G
Med Pregl; 1992; 45(7-8):262-5. PubMed ID: 1344453
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
Timmerman D; Van Calster B; Jurkovic D; Valentin L; Testa AC; Bernard JP; Van Holsbeke C; Van Huffel S; Vergote I; Bourne T
J Clin Oncol; 2007 Sep; 25(27):4194-200. PubMed ID: 17698805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]